The UK pharmaceutical giant has announced a landmark $15bn China investment during the UK prime minister’s visit, marking its largest expansion yet to boost manufacturing, R&D and biotech collaboration.

Hong Kong's finance chief discussed opportunities in the Northern Metropolis, developing AI, foreign tech firms entering the SAR, green finance, and China's evolving role in supply chains.

In a positive year for the region's banks, 2025 ECM fees in Apac, ex Japan, were up 45% from 2024, DCM fees saw 11% growth, amid a record year for bonds, while M&A advisory fees climbed 43%.

YP05002, developed by Yao Pharma, is in Phase 1 clinical development in Australia and can potentially help with metabolic diseases; Yao Pharma will receive an upfront payment of $150m for a worldwide licence.

HKEX to welcome Middle Eastern issuer soon, while Xiaomi hopes to bring its EV products to Europe.

Adam Zhang, managing director of Collabrium Partners, shares his views with FA on how Chinese companies are changing their approach to cross-border M&A, including finding opportunities in Southeast Asia and in technology.

The HK$155 a share offer is a 33% premium over Hang Seng's 30-day average closing price; HSBC already owns 63% of the HKEX-listed bank. Hang Seng's after tax profits declined 30% in H1 2025. HSBC has paused buybacks.

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.

The Chinese global PC firm has appointed a Middle East leadership team, while its regional headquarters will be in Riyadh's Al Majdoul Tower.

The Chinese telecom group's zero coupon, five-year, convertible bonds are listed on the HKEX and are convertible into fully paid H shares; the issuance follows recent ones from the likes of Henderson Land.